Logo
  • ABOUT US
  • PIPELINE & PUBLICATIONS
  • INVESTOR OVERVIEW
  • NEWS
  • ABOUT US
  • PIPELINE & PUBLICATIONS
  • INVESTOR OVERVIEW
  • NEWS
  • Corporate Governance
  • Careers
  • Contact
CONNECT WITH ALZAMEND
  • TWITTER
  • facebook

Press Releases

A Collection of Alzamend News & Updates

Featured Updates

Share
  • Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

    Data confirm the positive topline results announced in December 2021 demonstrating AL001 in plasma is bioequivalent to the marketed lithium carbonate product

    Results show that the shapes of the lithium plasma concentration versus time curves are similar to marketed product

    ATLANTA–(BUSINESS WIRE)– Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders,

  • Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021

  • Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

  • Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease

  • Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s

  • Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

LEARN MORE ALL UPDATES
    • March 2022
    Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

    Data confirm the positive topline results announced in December 2021 demonstrating AL001 in plasma is bioequivalent to the marketed lithium carbonate product

    Results show that the shapes of the lithium plasma concentration versus time curves are similar to marketed product

    ATLANTA–(BUSINESS WIRE)– Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders,

    LEARN MORE
    • January 2022
    Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021

    LEARN MORE
    • January 2022
    Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

    LEARN MORE
    • January 2022
    Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease

    LEARN MORE
    • January 2022
    Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s

    LEARN MORE
    • January 2022
    Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

    LEARN MORE
    • July 2021
    Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease

    TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (Nasdaq: ALZN) (“Alzamend”), a preclinical stage biopharmaceutical company, today announced that it submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase 1 clinical study of AL001 on June 30, 2021. The Phase 1, first-in-human study is for the purpose of determining potential clinically safe and appropriate AL001 dosing in future studies. AL001 is a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild,

    LEARN MORE
    • June 2021
    Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million

    Tampa, FL – (Business Newswire – June 17, 2021) – Alzamend Neuro, Inc. (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the closing of its initial public offering of 2,500,000 shares of its common stock and full exercise of the underwriter’s over-allotment option to purchase 375,000 additional shares of common stock at a price to the public of $5.00 per share.

    LEARN MORE
    • June 2021
    Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease

    Cocrystal Lithium-Based Therapy, “LiProSal™” Targets the Reduction of Agitation in Patients with AD

    Salt Lake City, UT – (Globe Newswire – October 29, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”) that, together, comprise the basis for a therapy targeted to treat agitation in those who are diagnosed with Alzheimer’s disease (AD). The therapy, named LiProSal™, combines lithium, proline and salicylate leveraging cocrystal technology to deliver relief to patients with AD and possibly other forms of dementia.

    LEARN MORE
    • June 2021
    Alzamend Neuro Announces Pricing of Initial Public Offering

    TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro, Inc. (“Alzamend”), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the pricing of its initial public offering of 2,500,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering to Alzamend, before deducting underwriting discounts and commissions and other offering expenses payable by Alzamend,

    LEARN MORE
    • March 2021
    Alzamend Neuro®, Inc. announces an agreement to sell $10,000,000 of its securities to Digital Power Lending LLC, a subsidiary of Ault Global Holdings, Inc.

    TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (“Alzamend”) today announced that it has entered into a securities purchase agreement with Digital Power Lending, LLC (“DPL”), a wholly owned subsidiary of Ault Global Holdings, Inc. (“AGH”), a related party. Pursuant to the securities purchase agreement, DPL agreed to invest an aggregate of $10,000,000 in our common stock and warrants. DPL funded $4,000,000 in connection with the execution of the securities purchase agreement and will fund the balance upon Alzamend achieving certain milestones related to the U.S.

    LEARN MORE
    • December 2020
    Alzamend Neuro®, Inc. Announces Confidential Submission of Draft Registration Statement Relating to the Proposed Initial Public Offering of Its Common Stock

    TAMPA, Fla.–(BUSINESS WIRE)–Alzamend Neuro®, Inc. (“Alzamend” or the “Company”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”). The public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.

    This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities,

    LEARN MORE
    • November 2020
    Alzamend Neuro®, Inc. Registration is Closing to Join the Shareholder and Investor Conference Call and Webcast set for Tomorrow, November 17, 2020 to Provide Update and Plans for 2021

    Tampa. FL – (Business Newswire – November 16, 2020) – Alzamend Neuro®, Inc. (“Alzamend®” or the “Company”) reminds shareholders, investors and all interested parties that mandatory registration is closing Tuesday morning for the conference call and webcast to be held that day November 17th at 5:00pm ET (2:00pm PT) led by Alzamend’s Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, Alzamend’s CEO and Director. The conference call and webcast will provide an update on the Company’s activities and accomplishments and present the Company’s plans for 2021.

    LEARN MORE
    • November 2020
    Alzamend Neuro®, Inc. Announces Shareholder and Investor Conference Call and Webcast to Provide Update and Plans for 2021

    Tampa. FL – (Business Newswire – November 3, 2020) – Alzamend Neuro®, Inc. (“Alzamend®” or the “Company”) announced today that the Company will host a conference call and webcast led by its Founder and Chairman, Milton “Todd” Ault, III, and Stephan Jackman, Company’s CEO and Director, on Tuesday, November 17th at 5:00pm ET (2:00pm PT). The conference call and webcast will provide an update on the Company’s activities and accomplishments and present the Company’s plans for 2021.

    LEARN MORE
    • October 2020
    New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression

    Tampa, FL, October 27, 2020 – Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer’s Association. Currently, Amyloid-β buildup in the brain is believed to be the cause of Alzheimer’s among many researchers. There have been many attempts to prevent or reverse the disease by targeting Amyloid-β including the first vaccine clinical trial as AN-1792 in 2002 by Elan, which targeted Amyloid-β proteins. Unfortunately,

    LEARN MORE
    • July 2019
    Alzamend Neuro™ Announces Appointment of Dr. Eric McDade to Its Scientific Advisory Board

    Company Selects Innovative Researcher and Leader, Associate Director of DIAN-TU

    Tampa, FL – (Business Newswire – July 16, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed Eric McDade, DO, a board-certified cognitive neurologist, as its next member to its Scientific Advisory Board. Dr. McDade, an innovative researcher and leader since 2010, has focused his activities on the evaluation of those with dementia syndromes and on developing a clinical research program that focuses on using brain imaging and cerebrospinal fluid markers to identify those at risk for Alzheimer disease (“AD”).

    LEARN MORE
    • July 2019
    Alzamend Neuro™ Announces Senior Management to Participate in the 2019 Alzheimer’s Association International Conference®

    Tampa, FL – (Business Newswire – July 12, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that its senior management team led by Stephan Jackman, the Company’s CEO and Ken Cragun, the Company’s CFO will be participating in the annual Alzheimer’s Association International Conference® being held in Los Angeles, CA from July 12 through July 18, 2019 at the L.A. Convention Center. Also attending will be the Company’s Executive Chairman, Milton “Todd” Ault,

    LEARN MORE
    • July 2019
    Alzamend Neuro™ Announces First Appointment to Scientific Advisory Board

    Appoints Dr. Thomas Wisniewski, Leading Pioneer in Alzheimer’s Disease

    Tampa, FL – (Business Newswire – July 9, 2019) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed its first member to its Scientific Advisory Board, Dr. Thomas Wisniewski, a leading and acclaimed pioneer in the study and treatment of Alzheimer’s Disease. Dr. Wisniewski is a board-certified neurologist and neuropathologist and is the Director of the NYU Pearl Barlow Center for Memory Evaluation and Treatment who operates an active research laboratory focusing on neurodegenerative disorders with a particular focus on the mechanisms that drive amyloid deposition in Alzheimer’s and prion diseases.

    LEARN MORE
    • December 2018
    Alzamend Neuro™ Completes New Management Team for 2019

    Appoints Financial Executive, Kenneth S. Cragun, as New CFO and Treasurer

    Tampa, FL – (Globe Newswire – December 26, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed top-tier financial executive, Kenneth S. Cragun, CPA, as its new Chief Financial Officer (CFO) and Treasurer. Mr. Cragun will report directly to the Company’s Board of Directors. The selection of Mr. Cragun fulfills the Company’s goal of building a robust management team of accomplished professionals to lead the Company into 2019 and to the next level.

    LEARN MORE
    • November 2018
    Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman

     

    Salt Lake City, UT – (Globe Newswire – November 19, 2018) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief Executive Officer in fulfillment of its goal to attract and secure a full-time proven industry leader to move the Company to the next level. Mr. Jackman has over twenty years of multi-industry experience in administration,

    LEARN MORE
    • October 2018
    Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease

    Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) — Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”) that, together, comprise the basis for a therapy targeted to treat agitation in those who are diagnosed with Alzheimer’s disease (AD). The therapy, named LiProSal™, combines lithium, proline and salicylate leveraging cocrystal technology to deliver relief to patients with AD and possibly other forms of dementia.

    LEARN MORE
    • October 2017
    Alzamend Neuro™ Launches Pursuit to Secure FDA IND and First Stage Clinicals

    Company Selects TAMM Net as FDA Consultant to Lead Regulatory Actions for USF Treatment

    Salt Lake City, UT – (Globe Newswire – October 24, 2017) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has selected TAMM Net of Marietta, GA to lead its FDA regulatory application and oversight efforts including the successful filing of a FDA IND application and resulting in FDA approval to conduct a First Stage Clinical Trial for CAO22W.

    LEARN MORE
    • October 2017
    Alzamend Neuro Launches Regulation A+ Tier II SEC Qualified Offering Pursues $50 MM Raise, Licenses with Dr. Cao & USF Health Byrd Alzheimer’s Institute

    Salt Lake City, UT – (Marketwired – January 3, 2017) – Alzamend Neuro, Inc. (Alzamend) announced today it has launched its Regulation A+ Tier II Offering online at www.AlzamendRegA.com . The Company’s campaign targeted to raise $50MM in equity capital can take investment immediately. On December 8, 2016, the Company was notified by the SEC that it had qualified its Form 1A Application allowing the Company to move forward with the Offering which will leverage the key component of the Reg.

    LEARN MORE
    • January 2017
    USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders

    Alzamend Neuro™ has Licensed the USF Treatment to Help Advance Commercialization

    Salt Lake City, UT – (Globe Newswire – January 30 2017) – Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) reprints by permission of the University of South Florida (USF) Technology Transfer Office this press release published on January 19, 2017.

    A neuroscientist at the USF Health Byrd Alzheimer’s Institute and the USF College of Pharmacy has developed an immunotherapeutic treatment now undergoing testing for the prevention,

    LEARN MORE
    • January 2017
    USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders

    TAMPA, Fla., January 19, 2017 — Alzamend Neuro™ has licensed the USF treatment to help advance commercialization. A neuroscientist at the USF Health Byrd Alzheimer’s Institute and the USF College of Pharmacy has developed an immunotherapeutic treatment now undergoing testing for the prevention, treatment and cure of Alzheimer’s disease as well as other neurological disorders. This innovative technology has been exclusively licensed from USF to Alzamend Neuro™, Inc.

    Chuanhai Cao, a USF associate professor of pharmaceutical sciences and a researcher at the USF Health Byrd Alzheimer’s Institute,

    LEARN MORE
SUBSCRIBE TO OUR UPDATES:
Logo

Making Alzheimer's Just a Memory™

  • Alzamend Neuro is a registered mark of Alzamend Neuro Inc.
  • Copyright © 2016 - 2022 Alzamend Neuro Inc. All rights reserved.